Article
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.
Targeted oncology - 1 Jan 2022
Lin Lishi, Smit Egbert F, de Langen Adrianus J, van Balen Dorieke E M, Beijnen Jos H, Huitema Alwin D R
Abstract excerpt
BACKGROUND: Overall survival (OS) data of osimertinib in pretreated non-small-cell lung cancer (NSCLC) in real-world practice is limited, and treatment benefits for patients not represented in the pivotal trials (ineligible) are unclear. OBJECTIVE: To determine the representativeness of the AURA3 trial for NSCLC patients treated with osimertinib in a real-world setting and to determine outcomes of patients who...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.